share_log

Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate

Benzinga ·  Dec 12 20:42

EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.

Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment